Oral fosfomycin activity against Klebsiella pneumoniae in a dynamic bladder infection in vitro model
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Antimicrobial Chemotherapy"
DOI: 10.1093/jac/dkac045
Abstract: Abstract Introduction The use of oral fosfomycin for urinary tract infections (UTIs) caused by non-Escherichia coli uropathogens is uncertain, including Klebsiella pneumoniae, the second most common uropathogen. Methods A multicompartment bladder infection in vitro model… read more here.
Keywords: fosfomycin; klebsiella pneumoniae; oral fosfomycin; bladder infection ... See more keywords
1526. Oral Fosfomycin Use for Urinary Tract Infections and Its Clinical Impact on Hospital Stay
Sign Up to like & getrecommendations! Published in 2018 at "Open Forum Infectious Diseases"
DOI: 10.1093/ofid/ofy210.1355
Abstract: Abstract Background Oral fosfomycin is a treatment option for urinary tract infections (UTI) caused by multi-drug-resistant organisms (MDRO). The objective of the study was to describe the prescribing pattern of fosfomycin and determine its role… read more here.
Keywords: urinary tract; use; fosfomycin use; tract infections ... See more keywords
2392. Fosfomycin Utilization and Outcomes in a Large VA Medical Center Over a Decade
Sign Up to like & getrecommendations! Published in 2018 at "Open Forum Infectious Diseases"
DOI: 10.1093/ofid/ofy210.2045
Abstract: Abstract Background Urinary tract infection (UTI) is one of the most common infectious diagnoses and in 2007 accounted for 10.5 million primary care visits in the US Advancing age and comorbidities, such as chronic kidney… read more here.
Keywords: cystitis; medical center; treatment; fosfomycin ... See more keywords
The role of fosfomycin for multidrug-resistant gram-negative infections.
Sign Up to like & getrecommendations! Published in 2019 at "Current Opinion in Infectious Diseases"
DOI: 10.1097/qco.0000000000000597
Abstract: PURPOSE OF REVIEW In the last decade, an increasing interest in using fosfomycin for the treatment of multidrug-resistant gram-negative (MDR-GNB) infections have been registered, especially when none or only a few other active alternatives remained… read more here.
Keywords: multidrug resistant; mdr gnb; gram negative; gnb ... See more keywords
Biopsy‐proven acute interstitial nephritis due to fosfomycin in a child
Sign Up to like & getrecommendations! Published in 2018 at "Nephrology"
DOI: 10.1111/nep.13197
Abstract: A one-year-old girl with a medical history of haemorrhagic enteritis was treated with fosfomycin, administered orally. After 5 days of treatment, the infant developed severe acute kidney injury, and was referred to our hospital for… read more here.
Keywords: biopsy; interstitial nephritis; fosfomycin; acute interstitial ... See more keywords
Amikacin Combined with Fosfomycin for Treatment of Neonatal Sepsis in the Setting of Highly Prevalent Antimicrobial Resistance
Sign Up to like & getrecommendations! Published in 2021 at "Antimicrobial Agents and Chemotherapy"
DOI: 10.1128/aac.00293-21
Abstract: Antimicrobial resistance (particularly through extended-spectrum β-lactamase and aminoglycoside-modifying enzyme production) in neonatal sepsis is a global problem, particularly in low- and middle-income countries, with significant mortality rates. High rates of resistance are reported for the… read more here.
Keywords: sepsis; combination; fosfomycin; antimicrobial resistance ... See more keywords
Use of Calgary and Microfluidic BioFlux Systems To Test the Activity of Fosfomycin and Tobramycin Alone and in Combination against Cystic Fibrosis Pseudomonas aeruginosa Biofilms
Sign Up to like & getrecommendations! Published in 2017 at "Antimicrobial Agents and Chemotherapy"
DOI: 10.1128/aac.01650-17
Abstract: ABSTRACT Pseudomonas aeruginosa is a major cause of morbidity and mortality in chronically infected cystic fibrosis patients. Novel in vitro biofilm models which reliably predict the therapeutic success of antimicrobial therapies against biofilm bacteria should… read more here.
Keywords: combination; cystic fibrosis; tobramycin; fosfomycin ... See more keywords
Oral Fosfomycin Efficacy with Variable Urinary Exposures following Single and Multiple Doses against Enterobacterales: the Importance of Heteroresistance for Growth Outcome
Sign Up to like & getrecommendations! Published in 2020 at "Antimicrobial Agents and Chemotherapy"
DOI: 10.1128/aac.01982-19
Abstract: Oral fosfomycin trometamol is licensed as a single oral dose for the treatment of uncomplicated urinary tract infections, with activity against multidrug-resistant uropathogens. The impact of interindividual variability in urinary concentrations on antimicrobial efficacy, and… read more here.
Keywords: urinary exposures; efficacy; multiple doses; fosfomycin ... See more keywords
Activity of Fosfomycin and Amikacin against Fosfomycin-Heteroresistant Escherichia coli Strains in a Hollow-Fiber Infection Model
Sign Up to like & getrecommendations! Published in 2021 at "Antimicrobial Agents and Chemotherapy"
DOI: 10.1128/aac.02213-20
Abstract: We evaluated human-like the efficacy of intravenous doses of fosfomycin of 8 g every 8 h (8 g/Q8h) and of amikacin (15 mg/kg/Q24h) in monotherapy and in combination against six fosfomycin-heteroresistant Escherichia coli isolates using a… read more here.
Keywords: coli; fosfomycin heteroresistant; fosfomycin amikacin; fosfomycin ... See more keywords
High-Dosage Fosfomycin Results in Adequate Plasma and Target-Site Exposure in Morbidly Obese and Nonobese Nonhyperfiltration Patients
Sign Up to like & getrecommendations! Published in 2022 at "Antimicrobial Agents and Chemotherapy"
DOI: 10.1128/aac.02302-21
Abstract: The objectives of this study were the identification in (morbidly) obese and nonobese patients of (i) the most appropriate body size descriptor for fosfomycin dose adjustments and (ii) adequacy of the currently employed dosing regimens.… read more here.
Keywords: fosfomycin; morbidly obese; target site; obese nonobese ... See more keywords
Pharmacokinetics and Pharmacodynamics of Fosfomycin and Its Activity against Extended-Spectrum-β-Lactamase-, Plasmid-Mediated AmpC-, and Carbapenemase-Producing Escherichia coli in a Murine Urinary Tract Infection Model
Sign Up to like & getrecommendations! Published in 2018 at "Antimicrobial Agents and Chemotherapy"
DOI: 10.1128/aac.02560-17
Abstract: ABSTRACT Fosfomycin has become an attractive treatment alternative for urinary tract infections (UTIs) due to increasing multidrug resistance (MDR) in Escherichia coli. In this study, we evaluated the pharmacokinetic (PK) and pharmacodynamic (PD) indices of… read more here.
Keywords: urinary tract; escherichia coli; mdr; fosfomycin ... See more keywords